Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Kymera Therapeutics Inc is a biotechnology business based in the US. Kymera Therapeutics shares (KYMR) are listed on the NASDAQ and all prices are listed in US Dollars. Kymera Therapeutics employs 143 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $21.10 |
|---|---|
| 52-week range | $13.15 - $69.12 |
| 50-day moving average | $19.54 |
| 200-day moving average | $42.47 |
| Wall St. target price | $63.08 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.49 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $21.1 from 2022-07-01
| 1 week (2022-06-24) | 4.82% |
|---|---|
| 1 month (2022-06-02) | 44.13% |
| 3 months (2022-03-30) | -49.17% |
| 6 months (2022-01-03) | -67.38% |
| 1 year (2021-07-02) | -62.61% |
|---|---|
| 2 years (2020-06-29) | N/A |
| 3 years (2019-06-29) | N/A |
| 5 years (2017-06-29) | N/A |
| Revenue TTM | $63.8 million |
|---|---|
| Gross profit TTM | $-64,185,000 |
| Return on assets TTM | -15.12% |
| Return on equity TTM | -35.18% |
| Profit margin | -194.23% |
| Book value | $8.31 |
| Market capitalisation | $1.1 billion |
TTM: trailing 12 months
We're not expecting Kymera Therapeutics to pay a dividend over the next 12 months.
Kymera Therapeutics, Inc. , a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.